Earlier this year, while speaking with Fierce Medtech at the annual J.P. Morgan Healthcare Conference, Dexcom CEO Kevin Sayer noted that the continuous glucose monitor maker had recently changed its ...

Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up its use to adults with Type 2 diabetes. The Control-IQ+ program—now with the added ...

Over the course of 52 weeks, people with type 2 diabetes saw a greater average reduction in HbA1c with icodec compared with glargine U100 (estimated between-group difference -0.19%, 95% CI -0.36% to ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. First, let me ...

Researchers observed a decrease in mean HbA1c from baseline to week 52 from 8.20 to 7.05% with efsitora and from 8.28 to 7.08% with glargine. HealthDay News — Once-weekly insulin efsitora alpha ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The 2025 ADA Standards of Care includes updated ...

New State of Type 2 Report in the United States reports that a majority of healthcare professionals (HCPs) surveyed believe continuous glucose monitoring will have the potential to be more impactful ...

CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the phase III QWINT development program found. In QWINT-1, there was a similar ...

Pre-exercise medical clearance is generally unnecessary for asymptomatic individuals prior to beginning low-intensity or moderate-intensity physical activity not exceeding the demands of brisk walking ...

Share on Pinterest Mounjaro appears to be a safe and effective adjunct therapy to slow-release insulin for treating uncontrolled diabetes. Mohammed Al Ali/Shutterstock Tirzepatide, Mounjaro, is ...